As an independent family company, DR. KADE has been developing, producing, and marketing high-quality medicines since 1886 for applications in gynecology, proctology, andrology, gastroenterology, pain treatment and vitamine/nutritional supplements. You can see the key facts and figures here.
The total turnover of the business activities of DR. KADE in the business year 2017/18 added up to approx. 131 million EUR, of which around 87 % was generated in our core market Germany. Around 43 % of the domestic turnover was generated with non-prescription drugs for self-medication (over-the-counter).
Through sales cooperations and joint ventures, DR. KADE is also active in Europe and outside of Europe, where approx. 13 % of the turnover is generated. At the moment the most important foreign markets for DR. KADE are Japan (with Maruho, since 1923) and Poland (with Kadefarm). Russia and Scandinavia are steadily gaining importance for the company.
DR. KADE Pharmazeutische Fabrik GmbH
||Berlin, Rigistraße und Ullsteinhaus
||~ 131 mil. €
|Areas of Application
||Gynecology, Proctology, Andrology, Gastroenterology, Pain Treatment, Vitamine/Nutritional Supplements
||Posterisan akut, KadeFungin 3, Trancolong, Utrogest, Oekolp, Androtop, Testogel, Gynokadin, Sanostol, FAKTU lind, RIOPAN